Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology

Fairfax, VA US
September 27, 2024 to September 28, 2024

Program Description

This two-day conference aimed at improving the knowledge and competence of academic and community oncology providers involved in Early Phase Clinical Trial Development and Management, Phase I/II Clinical Trials Conduct, and Management of Assessments and Safety Parameters involves more than the development of Concepts.

Recent Phase I Studies involving biomarker-guided design in the era of novel therapies has special challenges in selection of studies, patients’ enrollment along with networking with the surrounding institutions to ensure equity and inclusion of patients enrolled in the early phase studies that direct future drug development.

The activity will use a mix of didactic lectures and panel discussions to highlight various aspects of Early Phase Clinical Studies, Precision oncology, and addressing current challenges and opportunities in designing clinical trials in the era of novel therapies.

In-Person Only

This event is being offered as an in-person conference only.  There will be no virtual piece or recorded sessions.  Attendees will have the opportunity to join the speakers in-person at Inova Center for Personalized Health Conference Center (ICPH) .  

Questions & Refunds

If at any time you have questions, please email: Christina.fontana@inova.org

 

Target Audience

  • Advanced Practice Providers
  • Dietitians
  • Family Medicine
  • Genetic Counselors
  • Internists
  • Medical Oncologists
  • Nurses
  • Nurse Navigators
  • Pharmacists
  • Physicians
  • Radiation Oncologists
  • Radiologists
  • Residents, Students, and Fellows
  • Other Allied Health professionals and Trainees

Learning Objectives

  • Review challenges and trends in early drug development in the era of novel therapies.

  • Outline the best practices for the conduct of Phase I/II clinical trials in the era of novel therapies.

  • Identify phase I clinical trials to match patients’ needs.

  • Review the challenges and potential solutions for the diverse representation during drug development.


Questions about this event?  Contact Christina.fontana@inova.org

Course summary
Available credit: 
  • 16.50 AMA PRA Category 1 Credit
Course opens: 
03/01/2024
Course expires: 
12/31/2024
Event starts: 
09/27/2024 - 11:30am EDT
Event ends: 
09/28/2024 - 4:45pm EDT
Cost:
$350.00
Rating: 
0

Inova Center for Personalized Health Conference Center (ICPH)
8100 Innovation Park Drive
Entrance 3 - front door under Pedestrian Bridge
Fairfax, VA 22301
United States

Parking

Parking is complimentary at the Inova Center for Personalized Health Conference Center (ICPH) . Use surface lots E and F or parking garage for tower C. From the parking garage, take elevator to level 2, walk around the elevators to the bridge over to the conference center. 

Travel

Airports and Ground Transportation

Inova Center for Personalized Health Conference Center (ICPH)  is centrally located between Washington Dulles Airport (IAD) and Reagan Airports (DCA).  Union Station (in Washington, DC) is located about 30-40 minutes from the campus.  Both airports along with Union Station offer onsite ground transportation to Fairfax, VA which is about a 30–40-minute drive.  Uber or Lyft are also reliable ground transportation options in the DC metro area.

Hotels

Below are the two hotels that are located closest to the Inova Center for Personalized Health Conference Center (ICPH) and offer us discounted rates.

8296 Glass Alley, Fairfax, VA 22031

Phone: 571-327-2277

Inova/corporate rate code: 8296INOVA

 

3111 Fairview Park Dr, Falls Church, VA 22042

(703) 849-9400

    Program Director

    Nagla Abdel Karim, MD

    Director of Early Developmental Therapeutics

    Inova Schar Cancer Institute

    Professor of Medicine

    University of Virginia

     

    Advisory Committee:

    • Elad Sharon, MD
    • Rabih Said, MD, MPH

    Scientific Committee:

    • Vivek Subbiah, MD
    • Raymond Wadlow, MD
    • Teja Poosarla, MD
    • Maya Khalil

    Organizing Committee:

    • Ludimila Cavalcante, MD
    • Mathew Riley, MD

    Drug and Therapeutics Committee:

    • Safae Chouraichi, PharmD
    • Simona Armanca, PharmD

    Steering Committee:

    • Abdul Rafeh Naqash, MD
    • Ayham Deeb, MD

     

    Speaker Disclosure Statement

    Inova Health System’s Office of Continuing Medical Education adheres to ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, program directors, and planners are required to disclose all relevant financial relationships with ineligible entities as defined by ACCME.  All relevant financial relationships listed for these individuals have been mitigated.  

    Program Director(s)

    Nagla Karim

    has no relevant financial relationships to disclose at this time.
    Speaker(s)

    Germame Ajebo, MD

    has no relevant financial relationships to disclose at this time.

    Laura Alder, MD

    has a financial relationship (Contracted Research) with ORIC;.
    has a financial relationship (Other) with OncoHost ;.
    has a financial relationship (Contracted Research) with BerGenBio;.

    Minira Aslanova, DO

    has no relevant financial relationships to disclose at this time.

    Jennifer Bires

    has no relevant financial relationships to disclose at this time.

    Pamela Brandt, D.O.

    has no relevant financial relationships to disclose at this time.

    Timothy Cannon, MD, Associate Professor at University of Virginia Medical School

    has a financial relationship (Consulting Fee) with Intermountain health care;.

    Safae Chouraichi, PharmD, BCOP

    has no relevant financial relationships to disclose at this time.

    Andrew Ciupek

    has no relevant financial relationships to disclose at this time.

    Raymund Cuevo

    has no relevant financial relationships to disclose at this time.

    John Deeken, MD

    has no relevant financial relationships to disclose at this time.

    Jaydira Del Rivero

    has no relevant financial relationships to disclose at this time.

    Duy Duong, DO

    has no relevant financial relationships to disclose at this time.

    Bassel El-Rayes

    has no relevant financial relationships to disclose at this time.

    Lauren Fay, MPH, RD-AP, CSO, CNSC

    has no relevant financial relationships to disclose at this time.

    William Figg, Sr.

    has no relevant financial relationships to disclose at this time.

    Krishna Gunturu, Medical Oncologist, MD

    has a financial relationship (Consulting Fee) with BMS;.
    has a financial relationship (Consulting Fee) with Astra Zeneca;.

    Christopher Johnson, MD, PhD

    has no relevant financial relationships to disclose at this time.

    Nagla Karim

    has no relevant financial relationships to disclose at this time.

    Maya Khalil, MD

    has a financial relationship (Professional Services) with BeiGene;.
    has a financial relationship (Professional Services) with AstraZeneca Pharmaceuticals LP;.
    has a financial relationship (Professional Services) with Advenchen Pharmaceuticals, LLC;.
    has a financial relationship (Professional Services) with Taiho Pharmaceuticals Co., Ltd.;.
    has a financial relationship (Professional Services) with Other - NGM Pharmaceuticals;.
    has a financial relationship (Professional Services) with Bristol Myers Squibb;.
    has a financial relationship (Professional Services) with Other - Navire Pharma inc;.
    has a financial relationship (Professional Services) with Other - Guardant;.
    has a financial relationship (Professional Services) with Spectrum Pharmaceuticals, Inc;.
    has a financial relationship (Professional Services) with Genentech, Inc;.
    has a financial relationship (Professional Services) with Other - ARCUS BioSciences;.
    has a financial relationship (Professional Services) with Other - Innate Pharma;.
    has a financial relationship (Professional Services) with Other - Debiopharm Group;.
    has a financial relationship (Professional Services) with Takeda Pharmaceuticals North America, Inc.;.
    has a financial relationship (Professional Services) with Johnson & Johnson;.
    has a financial relationship (Professional Services) with Other - Dynamicure Biotech;.
    has a financial relationship (Professional Services) with Other - Nitto BioPharma;.
    has a financial relationship (Professional Services) with Astellas Pharma US, Inc;.
    has a financial relationship (Professional Services) with Caris Life Sciences;.
    has a financial relationship (Professional Services) with Boehringer Ingelheim GmbH;.
    has a financial relationship (Professional Services) with Other - Jounce Therapeutics;.
    has a financial relationship (Professional Services) with Merck & Co., Inc.;.
    has a financial relationship (Professional Services) with Regeneron Pharmactcls;.
    has a financial relationship (Professional Services) with National Cancer Institute;.
    has a financial relationship (Professional Services) with Other - Shanghai Henlius;.
    has a financial relationship (Professional Services) with Other - Numab Therapeutics;.
    has a financial relationship (Professional Services) with Other - I-Mab Biopharma;.
    has a financial relationship (Professional Services) with Abbvie, Inc.;.
    has a financial relationship (Professional Services) with Eli Lilly and Company;.
    has a financial relationship (Professional Services) with Other - TopAlliance Biosciences;.
    has a financial relationship (Professional Services) with Other - Xencor;.
    has a financial relationship (Professional Services) with Other - Summit;.
    has a financial relationship (Professional Services) with Other - Black Diamond Therapeutics;.
    has a financial relationship (Professional Services) with Amgen;.
    has a financial relationship (Professional Services) with SeaGen;.
    has a financial relationship (Professional Services) with Other - Cantargia;.
    has a financial relationship (Professional Services) with Janssen Pharmaceutica Products, LP;.

    Yufan Liu

    has no relevant financial relationships to disclose at this time.

    Daniel Margolis, MD

    has a financial relationship (Other) with Stratagen Bio;.
    has a financial relationship (Consulting Fee) with Guerbet, Inc;.
    has a financial relationship (Consulting Fee) with Promaxo, Inc;.

    Thomas Marron

    has a financial relationship (Consulting Fee) with Geneos;.
    has a financial relationship (Consulting Fee) with FATE;.
    has a financial relationship (Grant Or Contract) with Regeneron;.
    has a financial relationship (Consulting Fee) with Genentech;.
    has a financial relationship (Consulting Fee) with AstraZeneca;.
    has a financial relationship (Consulting Fee) with Astellas;.
    has a financial relationship (Grant Or Contract) with Boehringer Ingelheim;.
    has a financial relationship (Consulting Fee) with EMD Serono;.
    has a financial relationship (Consulting Fee) with STORM;.
    has a financial relationship (Consulting Fee) with Avammune;.
    has a financial relationship (Grant Or Contract) with BMS;.
    has a financial relationship (Consulting Fee) with Merck;.
    has a financial relationship (Consulting Fee) with AbbVie;.
    has a financial relationship (Consulting Fee) with Ono;.
    has a financial relationship (Consulting Fee) with Regeneron;.

    John Morris

    has no relevant financial relationships to disclose at this time.

    Nina Neill, MD, MS

    has no relevant financial relationships to disclose at this time.

    Ishan Patel, MD

    has no relevant financial relationships to disclose at this time.

    Faran Polani, MD

    has no relevant financial relationships to disclose at this time.

    Beverly Reigle, PhD, RN, FARN

    has no relevant financial relationships to disclose at this time.

    Triparna Sen, PhD

    has no relevant financial relationships to disclose at this time.

    Janakiraman Subramanian, MD, MPH

    has a financial relationship (Professional Services) with Regeneron/Sanofi;.
    has a financial relationship (Professional Services) with Jazz Pharma;.
    has a financial relationship (Professional Services) with Pfizer;.
    has a financial relationship (Professional Services) with Cancer Expert Now;.
    has a financial relationship (Professional Services) with Daiichi;.
    has a financial relationship (Professional Services) with Oncohost;.
    has a financial relationship (Professional Services) with Guidepoint;.
    has a financial relationship (Professional Services) with Astra Zeneca;.
    has a financial relationship (Professional Services) with G1 therapeutics;.
    has a financial relationship (Professional Services) with GLG;.
    has a financial relationship (Professional Services) with Janssen;.

    Kei Suzuki

    has no relevant financial relationships to disclose at this time.

    Brian Van Tine

    has a financial relationship (Consulting Fee) with Deciphera Pharmaceuticals;.
    has a financial relationship (Consulting Fee) with Putnam;.
    has a financial relationship (Consulting Fee) with Aadi;.
    has a financial relationship (Professional Services) with Total Health Conference;.
    has a financial relationship (Consulting Fee) with Boehringer Ingelheim;.
    has a financial relationship (Professional Services) with Curis;.
    has a financial relationship (Patent) with Accuronix Therapeutics;.
    has a financial relationship (Consulting Fee) with Advenchen;.
    has a financial relationship (Consulting Fee) with Acuta Capital ;.
    has a financial relationship (Professional Services) with Kronos Bio;.
    has a financial relationship (Travel) with Polaris;.
    has a financial relationship (Professional Services) with Iterion Therapeutics, Inc;.
    has a financial relationship (Grant Or Contract) with Polaris;.
    has a financial relationship (Consulting Fee) with EcoR1;.
    has a financial relationship (Consulting Fee) with Boxer Capital LLC;.
    has a financial relationship (Consulting Fee) with Kronos Bio;.
    has a financial relationship (Travel) with Adaptimmune;.
    has a financial relationship (Professional Services) with Agenus;.
    has a financial relationship (Consulting Fee) with Daiichi Sankyo Inc. ;.
    has a financial relationship (Consulting Fee) with Salarius Pharmaceuticals, Inc.,;.
    has a financial relationship (Consulting Fee) with Hinge Bio;.
    has a financial relationship (Professional Services) with Oncology Education;.
    has a financial relationship (Consulting Fee) with PTC Therapuetics;.

    Raymond Wadlow, MD

    has a financial relationship (Consulting Fee) with Seagen;.
    has a financial relationship (Consulting Fee) with Taiho;.
    has a financial relationship (Consulting Fee) with Exact Sciences;.
    has a financial relationship (Consulting Fee) with Pfizer;.
    has a financial relationship (Consulting Fee) with Bristol Myers Squibb;.

    Inova CME Accreditation

    The Medical Society of Virginia is a member of the Southern States CME Collaborative, an ACCME Recognized Accreditor. Inova Health System Office of Continuing Medical Education is accredited by the Southern States CME Collaborative to provide continuing medical education for physicians.

    Credit Designation

    The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 16.5 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 16.5 credits in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

     

    Nurse Credentialing FAQs

    For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME.  For more information visit,  https://www.nursingworld.org/certification/faqs/

     

    Available Credit

    • 16.50 AMA PRA Category 1 Credit

    Interested in Exhibiting? 

    General Exhibit Booth: $3,000

    • 6' undraped table with two chairs
    • Conference registration for two representatives
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email

     

    Premium Exhibitor Booth: $4,500

    • 6' undraped table with two chairs
    • Conference registration for three representatives
    • Access to sit-in on educational sessions
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email
    • Attendee registration list

     

    Nonprofit Organizations Booth - $500

    (501c3 must be submitted for approval)

    • 6' undraped table with two chairs
    • Conference registration for two representatives
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email

    Download the full prospectus here!  PDF icon <span style="color:#3498db">Evolving Therapies September 2024 PROSPECTUS FORM.pdf</span>


    Questions?  Email Christina Fontana for more information. 

     

    Price

    Cost:
    $350.00
    Please login or register to take this course.

    Registration Information:

    In order to view all the event information, please sign in or create an account.